---

---

sector : Professional, scientific, and technical services    tags : Trial   

save search

---

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial's lower-than-expected event rate suggests improved survival outcomes
Published: 2024-04-22 (Crawled : 13:00) - biospace.com/
PBLA | News | $0.4748 20K |

Professional, Scientific, and T...

| 11.9% | O: -4.76% H: 17.5% C: 17.5%
aspire for trial therapeutics

---

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.459 18K |

Professional, Scientific, and T...

| -25.96% | O: 0.11% H: 5.95% C: -13.78%
mc138 fda ttx-mc138 tumors clearance trial therapeutics advanced

---

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.38 18K |

Professional, Scientific, and T...

| 3.76% | O: -1.5% H: 0.0% C: -2.29%
brtx-100 disease trial

---

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Published: 2024-03-27 (Crawled : 13:30) - globenewswire.com
AVTE M | $22.565 1.78% 5.9K |

Professional, Scientific, and T...

| -13.57% | O: 6.78% H: 7.19% C: 4.05%
conference international trial therapeutics

---

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
UNCY | $1.15 57K |

Professional, Scientific, and T...

| -23.33% | O: -6.67% H: 10.71% C: 8.57%
trial therapeutics

---

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.17 4.1K |

Professional, Scientific, and T...

| -31.53% | O: 0.22% H: 3.45% C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy

---

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
Published: 2024-02-22 (Crawled : 12:30) - prnewswire.com
ELEV | $4.3 6.17% 46K |

Professional, Scientific, and T...

| 46.21% | O: -1.44% H: 5.49% C: -1.1%
eo-3021 first japan ongoing trial

---

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
BIXT A | $0.141 55K |

Professional, Scientific, and T...

| 19.76% | O: 0.0% H: 0.09% C: -5.9%
covid-19 drug antiviral trial

---

Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Published: 2024-01-29 (Crawled : 12:00) - prnewswire.com
ACXP | $1.98 1K |

Professional, Scientific, and T...

| -48.84% | O: 0.26% H: 1.55% C: -5.15%
cure positive ibezapolstat trial

---

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
PBLA | News | $0.4748 20K |

Professional, Scientific, and T...

| -87.12% | O: 2.47% H: 0.94% C: -13.1%
momentum pancreatic aspire trial

---

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
VERA | $41.47 5.98% 260K |

Professional, Scientific, and T...

| 129.91% | O: 30.79% H: 19.79% C: 13.7%
nephropathy origin positive trial therapeutics

---

Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Published: 2024-01-18 (Crawled : 13:00) - globenewswire.com
PBLA | News | $0.4748 20K |

Professional, Scientific, and T...

| -94.58% | O: -5.49% H: 0.0% C: -18.9%
publication trial therapy study

---

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Published: 2024-01-17 (Crawled : 12:00) - prnewswire.com
ACXP | $1.98 1K |

Professional, Scientific, and T...

| -58.32% | O: -24.21% H: 25.83% C: 25.56%
positive ibezapolstat trial

---

ROSEN, NATIONAL TRIAL LAWYERS, Encourages The Beauty Health Company Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SKIN
Published: 2023-12-25 (Crawled : 20:00) - prnewswire.com
BCLYF | $2.3 46K |

Finance

| 25.0% | O: 4.35% H: 0.0% C: 0.0%
SKIN | $3.365 2.91% 120K |

Professional, Scientific, and T...

| -0.61% | O: 0.0% H: 0.61% C: -1.52%
BCS | $9.645 1.31% 5.3M |

Finance

| 20.97% | O: -0.13% H: 1.78% C: 1.4%
SPWR | $2.145 0.23% 3.5M |

Producer Manufacturing

| -52.02% | O: 0.9% H: 8.67% C: 6.44%
company health deadline beauty skin trial

---

Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
UNCY | $1.15 57K |

Professional, Scientific, and T...

| 100.94% | O: 3.09% H: 5.08% C: 0.0%
first disease kidney dialysis trial therapeutics

---

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Published: 2023-12-11 (Crawled : 21:00) - globenewswire.com
CNTB | $1.35 13K |

Professional, Scientific, and T...

| 50.0% | O: -8.59% H: 5.75% C: -0.57%
biopharma global trial

---

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
Published: 2023-12-11 (Crawled : 15:30) - biospace.com/
ALZN | $0.685 1.4K |

Professional, Scientific, and T...

| -35.51% | O: -1.87% H: 0.0% C: -4.76%
al001 fda drug lithium trial

---

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
MOLN | $3.88 390 |

Professional, Scientific, and T...

| Email alert Add to watchlist
mp0533 first positive ongoing aml meeting trial molecular

---

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
IPSC | $3.16 3.61% 2.8K |

Professional, Scientific, and T...

| Email alert Add to watchlist
cnty-101 trial therapeutics potential

---

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
Published: 2023-12-07 (Crawled : 12:30) - globenewswire.com
XLO | $1.09 -0.91% 32K |

Professional, Scientific, and T...

| 24.99% | O: 4.53% H: 7.71% C: 0.0%
xtx101 trial therapeutics

---

Gainers vs Losers

88%

12%

Top 10 Gainers

MTTR | News M | $4.625 165.81% 5.5M |

AGBA | $2.46 96.8% 28M |

Finance

EDBL | News | $6.94 84.57% 1.4M |

CZOO | $7.74 55.11% 2.7M |

PALI | $7.64 54.97% 14M |

Manufacturing

OPRT | News | $3.19 41.78% 3M |

Finance

PEGY | $0.0629 37.34% 110M |

Manufacturing

ZAPP | $6.02 35.59% 95K |

n/a

MLEC | $1.87 33.57% 1.6M |

n/a

VNRX | $0.759 26.5% 390K |

Health Technology

---

Your saved searches

---